apatinib + irinotecan + S-1

Apatinib + irinotecan + S-1 is a combination chemotherapy and targeted therapy regimen, specifically referred to as the ApaIRIS regimen in clinical trial contexts. Apatinib is a selective small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2 (VEGFR-2), thereby inhibiting tumor angiogenesis and blood vessel formation. Irinotecan is a cytotoxic agent that acts as a DNA topoisomerase I inhibitor, leading to DNA damage and cell death. S-1 is an oral fluoropyrimidine combination consisting of tegafur (a 5-fluorouracil prodrug), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (an orotate phosphoribosyltransferase inhibitor). This specific combination is being evaluated by Fudan University in a Phase II clinical trial as a second-line treatment for patients with metastatic pancreatic cancer who have failed prior chemotherapy with albumin-bound paclitaxel plus gemcitabine.

Brand names

Aitan

Other names

Apatinib + Irinotecan + S-1 regimen